Listed

Vera Therapeutics, Inc.

VERANasdaqCIK 1831828HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$112.5m, Q2 FY2026
Net income−$109.5m, Q2 FY2026
Vera Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m16.1Research and development, Q3 FY2023, three months to 2023-09-30$16.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure20.8Research and development, Q4 FY2023, three months to 2023-12-31$20.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure23.2Research and development, Q1 FY2024, three months to 2024-03-31$23.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure29.3Research and development, Q2 FY2024, three months to 2024-06-30$29.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure40.3Research and development, Q3 FY2024, three months to 2024-09-30$40.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure33.3Research and development, Q4 FY2024, three months to 2024-12-31$33.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure41.3Research and development, Q1 FY2025, three months to 2025-03-31$41.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure58.2Research and development, Q2 FY2025, three months to 2025-06-30$58.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure56.5Research and development, Q3 FY2025, three months to 2025-09-30$56.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure59.3Research and development, Q4 FY2025, three months to 2025-12-31$59.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure86.0Research and development, Q1 FY2026, three months to 2026-03-31$86.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure60.1Research and development, Q2 FY2026, three months to 2026-06-30$60.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Operating income$m(21.8)Operating income, Q3 FY2023, three months to 2023-09-30−$21.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure(27.0)Operating income, Q4 FY2023, three months to 2023-12-31−$27.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(31.1)Operating income, Q1 FY2024, three months to 2024-03-31−$31.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure(37.3)Operating income, Q2 FY2024, three months to 2024-06-30−$37.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure(49.8)Operating income, Q3 FY2024, three months to 2024-09-30−$49.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure(48.9)Operating income, Q4 FY2024, three months to 2024-12-31−$48.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(57.2)Operating income, Q1 FY2025, three months to 2025-03-31−$57.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure(80.1)Operating income, Q2 FY2025, three months to 2025-06-30−$80.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure(83.9)Operating income, Q3 FY2025, three months to 2025-09-30−$83.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure(94.2)Operating income, Q4 FY2025, three months to 2025-12-31−$94.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(125)Operating income, Q1 FY2026, three months to 2026-03-31−$125.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure(112)Operating income, Q2 FY2026, three months to 2026-06-30−$112.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Interest expense$m0.9Interest expense, Q3 FY2023, three months to 2023-09-30$943.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0000950170-23-062139.Report this figure1.1Interest expense, Q4 FY2023, three months to 2023-12-31$1.1m. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-27, accession 0000950170-24-036729. Derived: 12-month figure less the 9-month figure.Report this figure1.9Interest expense, Q1 FY2024, three months to 2024-03-31$1.9m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-10, accession 0000950170-24-057292.Report this figure1.9Interest expense, Q2 FY2024, three months to 2024-06-30$1.9m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-08, accession 0000950170-24-094108.Report this figure1.9Interest expense, Q3 FY2024, three months to 2024-09-30$1.9m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure1.9Interest expense, Q4 FY2024, three months to 2024-12-31$1.9m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure1.8Interest expense, Q1 FY2025, three months to 2025-03-31$1.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure1.9Interest expense, Q2 FY2025, three months to 2025-06-30$1.9m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure2.0Interest expense, Q3 FY2025, three months to 2025-09-30$2.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure1.9Interest expense, Q4 FY2025, three months to 2025-12-31$1.9m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure1.8Interest expense, Q1 FY2026, three months to 2026-03-31$1.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure1.8Interest expense, Q2 FY2026, three months to 2026-06-30$1.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(20.1)Net income, Q3 FY2023, three months to 2023-09-30−$20.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure(25.7)Net income, Q4 FY2023, three months to 2023-12-31−$25.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(28.4)Net income, Q1 FY2024, three months to 2024-03-31−$28.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure(33.7)Net income, Q2 FY2024, three months to 2024-06-30−$33.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure(46.6)Net income, Q3 FY2024, three months to 2024-09-30−$46.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure(43.4)Net income, Q4 FY2024, three months to 2024-12-31−$43.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(51.7)Net income, Q1 FY2025, three months to 2025-03-31−$51.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure(76.5)Net income, Q2 FY2025, three months to 2025-06-30−$76.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure(80.3)Net income, Q3 FY2025, three months to 2025-09-30−$80.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure(91.1)Net income, Q4 FY2025, three months to 2025-12-31−$91.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(121)Net income, Q1 FY2026, three months to 2026-03-31−$121.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure(109)Net income, Q2 FY2026, three months to 2026-06-30−$109.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Diluted EPS$ per share(0.45)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figurenot reported(0.56)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure(0.62)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure(0.85)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figurenot reported(0.81)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure(1.20)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure(1.26)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figurenot reported(1.69)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure(1.52)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Basic EPS$ per share(0.45)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figurenot reported(0.56)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure(0.62)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure(0.85)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.85 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figurenot reported(0.81)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure(1.20)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure(1.26)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figurenot reported(1.69)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure(1.52)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure

Balance sheet

Cash and equivalents$48.9m, Q2 FY2026
Long-term debt$75.2m, Q2 FY2026
Shareholders' equity$407.8m, Q2 FY2026
Vera Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m27.4Cash and equivalents, Q3 FY2023, at 2023-09-30$27.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0000950170-23-062139.Report this figure45.7Cash and equivalents, FY2023, at 2023-12-31$45.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-28, accession 0000950170-25-029969.Report this figure69.1Cash and equivalents, Q1 FY2024, at 2024-03-31$69.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-10, accession 0000950170-24-057292.Report this figure25.1Cash and equivalents, Q2 FY2024, at 2024-06-30$25.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0000950170-24-094108.Report this figure27.3Cash and equivalents, Q3 FY2024, at 2024-09-30$27.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure92.6Cash and equivalents, FY2024, at 2024-12-31$92.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-077442.Report this figure55.1Cash and equivalents, Q1 FY2025, at 2025-03-31$55.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure49.1Cash and equivalents, Q2 FY2025, at 2025-06-30$49.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure57.8Cash and equivalents, Q3 FY2025, at 2025-09-30$57.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure355Cash and equivalents, FY2025, at 2025-12-31$354.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure114Cash and equivalents, Q1 FY2026, at 2026-03-31$114.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure48.9Cash and equivalents, Q2 FY2026, at 2026-06-30$48.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Current assets$m172Current assets, Q3 FY2023, at 2023-09-30$171.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062139.Report this figure172Current assets, FY2023, at 2023-12-31$172.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-28, accession 0000950170-25-029969.Report this figure416Current assets, Q1 FY2024, at 2024-03-31$416.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0000950170-24-057292.Report this figure395Current assets, Q2 FY2024, at 2024-06-30$394.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094108.Report this figure364Current assets, Q3 FY2024, at 2024-09-30$364.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure651Current assets, FY2024, at 2024-12-31$651.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-077442.Report this figure606Current assets, Q1 FY2025, at 2025-03-31$606.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure571Current assets, Q2 FY2025, at 2025-06-30$571.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure511Current assets, Q3 FY2025, at 2025-09-30$511.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure729Current assets, FY2025, at 2025-12-31$728.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure616Current assets, Q1 FY2026, at 2026-03-31$615.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure527Current assets, Q2 FY2026, at 2026-06-30$527.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Total assets$m176Total assets, Q3 FY2023, at 2023-09-30$175.6m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0000950170-23-062139.Report this figure176Total assets, FY2023, at 2023-12-31$175.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-28, accession 0000950170-25-029969.Report this figure419Total assets, Q1 FY2024, at 2024-03-31$419.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0000950170-24-057292.Report this figure397Total assets, Q2 FY2024, at 2024-06-30$397.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-094108.Report this figure369Total assets, Q3 FY2024, at 2024-09-30$368.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure656Total assets, FY2024, at 2024-12-31$655.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-077442.Report this figure610Total assets, Q1 FY2025, at 2025-03-31$610.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure579Total assets, Q2 FY2025, at 2025-06-30$578.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure518Total assets, Q3 FY2025, at 2025-09-30$517.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure735Total assets, FY2025, at 2025-12-31$734.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure622Total assets, Q1 FY2026, at 2026-03-31$621.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure533Total assets, Q2 FY2026, at 2026-06-30$533.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Current liabilities$m24.6Current liabilities, Q3 FY2023, at 2023-09-30$24.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062139.Report this figure22.3Current liabilities, FY2023, at 2023-12-31$22.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-28, accession 0000950170-25-029969.Report this figure14.5Current liabilities, Q1 FY2024, at 2024-03-31$14.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0000950170-24-057292.Report this figure18.4Current liabilities, Q2 FY2024, at 2024-06-30$18.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094108.Report this figure26.5Current liabilities, Q3 FY2024, at 2024-09-30$26.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure25.4Current liabilities, FY2024, at 2024-12-31$25.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-077442.Report this figure21.9Current liabilities, Q1 FY2025, at 2025-03-31$21.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure33.6Current liabilities, Q2 FY2025, at 2025-06-30$33.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure41.9Current liabilities, Q3 FY2025, at 2025-09-30$41.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure53.5Current liabilities, FY2025, at 2025-12-31$53.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure45.1Current liabilities, Q1 FY2026, at 2026-03-31$45.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure48.3Current liabilities, Q2 FY2026, at 2026-06-30$48.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Total liabilities$m51.9Total liabilities, Q3 FY2023, at 2023-09-30$51.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0000950170-23-062139.Report this figure73.9Total liabilities, FY2023, at 2023-12-31$73.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-28, accession 0000950170-25-029969.Report this figure65.8Total liabilities, Q1 FY2024, at 2024-03-31$65.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-10, accession 0000950170-24-057292.Report this figure69.4Total liabilities, Q2 FY2024, at 2024-06-30$69.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-094108.Report this figure79.5Total liabilities, Q3 FY2024, at 2024-09-30$79.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure78.5Total liabilities, FY2024, at 2024-12-31$78.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-077442.Report this figure75.2Total liabilities, Q1 FY2025, at 2025-03-31$75.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure110Total liabilities, Q2 FY2025, at 2025-06-30$110.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure119Total liabilities, Q3 FY2025, at 2025-09-30$118.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure130Total liabilities, FY2025, at 2025-12-31$130.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure122Total liabilities, Q1 FY2026, at 2026-03-31$122.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure125Total liabilities, Q2 FY2026, at 2026-06-30$125.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Long-term debt$m25.0Long-term debt, Q3 FY2023, at 2023-09-30$25.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-09, accession 0000950170-23-062139.Report this figure49.9Long-term debt, FY2023, at 2023-12-31$49.9m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2025-02-28, accession 0000950170-25-029969.Report this figure50.1Long-term debt, Q1 FY2024, at 2024-03-31$50.1m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-05-10, accession 0000950170-24-057292.Report this figure50.3Long-term debt, Q2 FY2024, at 2024-06-30$50.3m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-08-08, accession 0000950170-24-094108.Report this figure50.5Long-term debt, Q3 FY2024, at 2024-09-30$50.5m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure50.7Long-term debt, FY2024, at 2024-12-31$50.7m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-02-26, accession 0001193125-26-077442.Report this figure50.9Long-term debt, Q1 FY2025, at 2025-03-31$50.9m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure74.5Long-term debt, Q2 FY2025, at 2025-06-30$74.5m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure74.6Long-term debt, Q3 FY2025, at 2025-09-30$74.6m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure74.8Long-term debt, FY2025, at 2025-12-31$74.8m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure75.0Long-term debt, Q1 FY2026, at 2026-03-31$75.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure75.2Long-term debt, Q2 FY2026, at 2026-06-30$75.2m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure
Shareholders' equity$m124Shareholders' equity, Q3 FY2023, at 2023-09-30$123.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure102Shareholders' equity, FY2023, at 2023-12-31$101.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-077442.Report this figure354Shareholders' equity, Q1 FY2024, at 2024-03-31$353.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure328Shareholders' equity, Q2 FY2024, at 2024-06-30$327.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure289Shareholders' equity, Q3 FY2024, at 2024-09-30$289.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure577Shareholders' equity, FY2024, at 2024-12-31$577.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure535Shareholders' equity, Q1 FY2025, at 2025-03-31$535.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure468Shareholders' equity, Q2 FY2025, at 2025-06-30$468.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure399Shareholders' equity, Q3 FY2025, at 2025-09-30$398.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure605Shareholders' equity, FY2025, at 2025-12-31$604.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure500Shareholders' equity, Q1 FY2026, at 2026-03-31$499.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure408Shareholders' equity, Q2 FY2026, at 2026-06-30$407.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure

Cash flow

Operating cash flow−$100.3m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Share repurchases$0, Q4 FY2025
Vera Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(23.0)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$23.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123239. Derived: 9-month figure less the 6-month figure.Report this figure(25.1)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$25.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(33.8)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$33.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure(24.8)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$24.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0000950170-25-103022. Derived: 6-month figure less the 3-month figure.Report this figure(36.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$36.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001193125-25-266881. Derived: 9-month figure less the 6-month figure.Report this figure(39.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$39.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(54.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$54.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure(54.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$54.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342380. Derived: 6-month figure less the 3-month figure.Report this figure(61.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$61.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001193125-25-266881. Derived: 9-month figure less the 6-month figure.Report this figure(70.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$70.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure(107)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$106.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure(100)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$100.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342380. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0000950170-24-123239. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2023, three months to 2023-12-31$63.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure0.1Capital expenditure, Q2 FY2024, three months to 2024-06-30$89.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-05, accession 0000950170-25-103022. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2024, three months to 2024-09-30$238.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001193125-25-266881. Derived: 9-month figure less the 6-month figure.Report this figure0.6Capital expenditure, Q4 FY2024, three months to 2024-12-31$645.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2025, three months to 2025-03-31$187.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$208.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342380. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$133.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001193125-25-266881. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$23.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342380. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$mnot reported0.0Share repurchases, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reported0.0Share repurchases, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reported0.0Share repurchases, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-02-26, accession 0001193125-26-077442. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)71.84m, Q2 FY2026
Vera Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares27.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3027,215,874 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0000950170-23-062139.Report this figure37.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3137,667,566 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-10, accession 0000950170-24-057292.Report this figure44.3Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3044,269,772 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-094108.Report this figure44.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3044,363,419 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123239.Report this figure51.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3150,971,933 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-07, accession 0000950170-25-064733.Report this figure54.7Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3054,728,552 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0000950170-25-103022.Report this figure54.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3054,898,297 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure63.7Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3163,671,558 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure63.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3063,789,303 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure63.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3063,847,055 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001193125-25-266881.Report this figure71.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3171,476,595 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-212143.Report this figure71.8Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3071,838,008 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure

Shares outstanding: 72.06mShares outstanding, period not labelled, at 2026-07-2972,063,335 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342380.Report this figure at Jul 29, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.